Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: Supporting the Women's Health Initiative study

Journal of Obstetrics and Gynaecology Research

Volumn 30, Issue 4, 2004, Pages 297-302

  Nozaki, Masahiro ^a   Koera, Keiko ^a   Nagata, Hideaki ^a   Nakano, Hitoo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Breast cancer; Hormone replacement therapy; Informed consent; Japanese women; Risk

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HORMONE; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; FEMALE; HORMONE SUBSTITUTION; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MAMMOGRAPHY; TOMOGRAPHY; UNIVERSITY HOSPITAL;

AGED; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; JAPAN; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 4243125376     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2004.00197.x     Document Type: Article

References (38)

1. Ross RK, Paganini-Hill A, Gerkins VR et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980; 243: 1635-1639.
2. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832-838.
3. Mills PK, Beeson WL, Phillips RL, Fraser GE. Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer 1989; 64: 591-597.
4. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. NEJM 1989; 321: 293-297.
5. Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol 2002; 3: 303-311.
6. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. Risk of breast cancer with estrogen-progestin replacement therapy. Int J Gynaecol Obstet 2002; 76: 333-335.
7. ACOG Committee on Gynecological Practice. Committee opinion: number 262, December 2001. Risk of breast cancer with estrogen-progestin replacement therapy. Obstet Gynecol 2001; 98: 1181-1184.
8. Genazzani AR, Gadducci A, Gambacciani M. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy. Climacteric 2001; 4: 181-193.
9. Burkman RT, Collins JA, Greene RA. Current perspectives on benefits and risks of hormone replacement therapy. Am J Obstet Gynecol 2001; 285(2 Suppl.): S13-S23.
10. Moerman CJ, Van Hout BA, Bonneux L, Witteman JC. Post-menopausal hormone therapy: less favorable risk-benefit ratios in healthy Dutch women. J Intern Med 2000; 248: 143-150.
11. Dobashi K. Hormone replacement therapy and breast cancer. Jpn J Cancer Chemother 1999; 26: 871-876.
12. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
13. Chen WY, Colditz GA, Rosner B et al. Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer. Ann Intern Med 2002; 137: 798-804.
14. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942-944.
15. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: Scientific review. JAMA 2002; 288: 872-881.
16. Kobayashi S, Dobashi K. Hormone replacement therapy and breast cancer risk. J Jpn Menopause Soc 2002; 10: 71-76.
17. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
18. La Vecchia C, Brinton LA, McTiernan A. Menopause, hormone replacement therapy and cancer. Maturitas 2001; 39: 97-115.
19. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses' Health Study. Am J Epidemiol 2000; 152: 950-964.
20. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal post-menopausal breast. J Clin Endocrinol Metab 1999; 84: 4559-4565.
21. Lange CA, Richer JK, Horwitz KB. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 1999; 13: 829-836.
22. Iwase K. Hormone replacement therapy and breast cancer. Jpn J Clin Med 2000; 58(Suppl.): 557-562.
23. Sitruk-Ware R, Plu-Bureau G. Progestins and cancer. Gynecol Endocrinol 1999; 13(Suppl. 4): 3-9.
24. De Lignieres B. Effects of progestogens on the postmenopausal breast. Climacteric 2002; 5: 229-235.
25. Grimes DA, Lobo RA. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet Gynecol 2002; 100: 1344-1353.
26. Lippert C, Seeger H, Wallwiener D, Mueck AO. Comparison of the effects of continuous combined and sequential combined medroxyprogesterone acetate-estradiol treatment on the proliferation of MCF-7 cells. Climacteric 2000; 3: 271-277.
27. Verheul HA, Coelingh-Bennink HJ, Kenemans P et al. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas 2000; 36: 1-17.
28. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003; 97: 1387-1392.
29. Weiss LK, Burkman RT, Cushing-Haugen KL et al. Hormone replacement therapy regimens and breast cancer risk (1). Obstet Gynecol 2002; 100: 1148-1158.
30. Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: A systematic review. Am J Obstet Gynecol 2002; 186: 325-334.
31. Anonymous. Hormone replacement therapy and cancer. Gynecol Endocrinot 2001; 15: 453-465.
32. Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: A qualitative review. Obstet Gynecol 2001; 98: 498-508.
33. Delgado RC, Lubian Lopez DM. Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 2001; 38: 147-156.
34. Gajdos C, Tartter PI, Babinszki A. Breast cancer diagnosed during hormone replacement therapy. Obstet Gynecol 2000; 95: 513-518.
35. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: Results of the Iowa Women's Health Study. JAMA 1999; 281: 2091-2097.
36. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002; 287: 734-741.
37. Schaire C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-491.
38. Cobleigh MA, Norlock FE, Oleske DM, Starr A. Hormone replacement therapy and high S phase in breast cancer. JAMA 1999; 281: 1528-1530.